Why Capricor Therapeutics (CAPR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine thesis — one sentence
Capricor is a cash-burning, single-pipeline biotech with 148.8% upside to the analyst target but missed EPS in 3 of 4 quarters, 36% short interest and a confirmed downtrend.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business depends on one pipeline asset, Deramiocel, with donor hearts as a key supplier, flagged as 3 high-severity concentration risks. Bear case | The lead program advances without a regulatory setback over 12 months. | ↓Deteriorating |
| CounterA regulatory rejection or supply constraint would eliminate most of the company's value. | ||
Price of $9.53 sits 148.8% below the $23.71 analyst target, a reward-to-risk of 9.92 against 15.0% downside. Targets | Price rises at least 50% toward the $23.71 target within 12 months. | Tripped↓Deteriorating |
| CounterLight analyst coverage and binary pipeline outcomes mean the target is highly uncertain. | ||
Quality scores 1.6 out of 10 with negative free cash flow, no moat and a Piotroski F-Score score of 4.4. Quality breakdown | Cash burn is funded without dilution beyond 15% over 12 months. | →Stable |
| CounterContinued losses likely require new equity raises that dilute holders. | ||
Price is below the 200-day moving average with a -12.1% 30-day slope and short interest is 36%, with implied volatility at 644%. Risk breakdown | Short interest falls below 25% and price reclaims the 200-day average. | ↓Deteriorating |
| CounterHigh short interest in a deeply oversold name can fuel a sharp squeeze on positive pipeline news. | ||
Capricor missed EPS estimates in 3 of the last 4 reported quarters with an average surprise of -28.1%, the latest -78.59%. Earnings | EPS surprise stays above -10% in the next 2 quarters. | ↑Improving |
| CounterFor a pre-revenue biotech, EPS misses mostly reflect trial spending timing rather than business failure. | ||
The business depends on one pipeline asset, Deramiocel, with donor hearts as a key supplier, flagged as 3 high-severity concentration risks.
↓Deteriorating- Expectation
- The lead program advances without a regulatory setback over 12 months.
CounterA regulatory rejection or supply constraint would eliminate most of the company's value.
Price of $9.53 sits 148.8% below the $23.71 analyst target, a reward-to-risk of 9.92 against 15.0% downside.
Tripped↓Deteriorating- Expectation
- Price rises at least 50% toward the $23.71 target within 12 months.
CounterLight analyst coverage and binary pipeline outcomes mean the target is highly uncertain.
Quality scores 1.6 out of 10 with negative free cash flow, no moat and a Piotroski F-Score score of 4.4.
→Stable- Expectation
- Cash burn is funded without dilution beyond 15% over 12 months.
CounterContinued losses likely require new equity raises that dilute holders.
Price is below the 200-day moving average with a -12.1% 30-day slope and short interest is 36%, with implied volatility at 644%.
↓Deteriorating- Expectation
- Short interest falls below 25% and price reclaims the 200-day average.
CounterHigh short interest in a deeply oversold name can fuel a sharp squeeze on positive pipeline news.
Capricor missed EPS estimates in 3 of the last 4 reported quarters with an average surprise of -28.1%, the latest -78.59%.
↑Improving- Expectation
- EPS surprise stays above -10% in the next 2 quarters.
CounterFor a pre-revenue biotech, EPS misses mostly reflect trial spending timing rather than business failure.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.2 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 9.1 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 2.1 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -12.0%/30d — confirmed downtrend
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.4 |
| Analyst rating | 6.6 |
| Price target | 10.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 218%
Insider
5.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
| notable moves | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.0 |
| support resistance | 4.8 |
| 52w position | 0.0 |
| gap | 4.0 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 5.3 |
| volatility | 0.0 |
| put call | 4.5 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 8.4 |
| debt equity | 8.2 |
- ▸High short interest justified: 36%
- ▸High IV: 679%
- ▸Above max pain $1
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 0B/3M
How the verdict was assembled
Quality below minimum threshold.
Engine technical detail
L1:HARD_BLOCK:QUALITY_FLOOR- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.60
- EARNINGS_PROXIMITY:114d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
- MOMENTUM:4.4<4.5
- DEATH_CROSS:HARD_BLOCK
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
SetupRecovery — Death cross but MACD improving, RSI 60
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -79% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.4<4.5 outcome against Sentiment at 7.6 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 7.6, Insider at 5.3, and Value at 5.0; the weakest are Quality at 1.6, Peer rank at 3.0, and Technical at 3.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Target UpsideTripped
Trip ifPrice falls below the stop-loss of $8.86 or the analyst target drops below $15.
- P2Single Pipeline Concentration
Trip ifRegulator issues a rejection of Deramiocel, dropping price more than 50% in a day.
- P3Cash Burn Weak Quality
Trip ifShare count increases by more than 20% from dilution.
- P4Downtrend Heavy Short Interest
Trip ifShort interest rises above 45% of float.
- P5Repeated Earnings Misses
Trip ifEPS surprise stays below -25% for 2 more consecutive quarters.